To examine the cellular and molecular impacts of diabetic metabolic disorders on intervertebral disc degeneration (IDD) and to elucidate the mechanisms involved.
Approach:
Key Findings:
Diabetes mellitus is significantly associated with the onset and progression of intervertebral disc degeneration.
Metabolic disorders and vascular lesions from hyperglycemia contribute to accelerated IDD.
Advanced glycation end products (AGEs) and oxidative stress play critical roles in the degeneration process.
Diabetic patients experience more severe and complex spinal degeneration.
Interpretation:
Understanding the connection between diabetes and IDD is crucial for developing new prevention and treatment strategies, as current research lacks comprehensive integration of findings.
Limitations:
Most studies focus on individual pathways rather than a holistic view of the mechanisms involved.
The precise molecular mechanisms of diabetes-induced IDD remain inadequately understood.
Conclusion:
The review provides a theoretical framework and practical recommendations for targeted metabolic therapy strategies to manage spinal degenerative disorders and improve patient quality of life.
Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
